Overview

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Status:
Not yet recruiting

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Summary

This study is being done to answer the following question: Can testing breastcancer for DNA abnormalities or "biomarkers" help predict which patients aremost likely to be helped by certain treatments? The pre-study screening isbeing done to test a sample of blood (or tumour tissue) for biomarkers to see ifpatients can participate in the study

Phase:

Phase 2

Details

Lead Sponsor:

Canadian Cancer Trials Group

Treatments:

Gemcitabine